文献速递胸部肿瘤

LIF诱导的肿瘤可塑性在LKB1突变肺癌中建立免疫抑制髓系生态位

LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.
PubMed 文献 · Cancer Discov · 2026-01-01

该研究利用基因工程小鼠模型和人类肿瘤样本,发现LKB1缺失导致白血病抑制因子(LIF)高表达,通过癌细胞自分泌环路招募免疫抑制性SiglecFHi中性粒细胞和Arg1+间质巨噬细胞。在Lkb1突变肺肿瘤中敲除LIF受体Lifr,揭示自分泌LIF信号诱导肿瘤可塑性并出现Sox17+去分化炎症细胞状态。抗体中和LIF可选择性消除Sox17+肿瘤细胞状态、减少免疫抑制髓系细胞并增强抗肿瘤T细胞应答,提示LIF是LKB1突变肺癌的潜在治疗靶点。

要点

  • LKB1缺失通过自分泌LIF信号诱导Sox17+去分化炎症肿瘤状态并招募免疫抑制髓系细胞。
  • 抗体中和LIF可消除Sox17+肿瘤细胞、减少免疫抑制髓系细胞并增强抗肿瘤T细胞应答。
  • LIF是LKB1突变肺癌这一缺乏有效靶向治疗亚型的潜在治疗靶点。

核心结论

  • LKB1-LIF轴驱动LKB1突变肺癌免疫逃逸,中和LIF可恢复抗肿瘤免疫。

研究设计与样本

  • 研究使用基因工程小鼠模型和人类肿瘤样本,并在Lkb1突变肺肿瘤中遗传敲除Lifr。

主要发现

  • LKB1缺失导致LIF高表达,通过癌细胞自分泌环路招募免疫抑制性SiglecFHi中性粒细胞和Arg1+间质巨噬细胞。
  • 自分泌LIF信号诱导肿瘤可塑性并出现Sox17+去分化炎症细胞状态。
  • 抗体中和LIF选择性消除Sox17+肿瘤细胞状态、减少免疫抑制髓系细胞并增强抗肿瘤T细胞应答。

临床怎么用

  • LKB1突变肺癌中LIF高表达,抗LIF治疗可消除Sox17+肿瘤状态并恢复抗肿瘤免疫。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: LKB1 mutations in lung cancer promote an immunosuppressive tumor microenvironment, but the underlying mechanisms remain unknown. Using genetically engineered mouse models and human tumor samples, we demonstrate that LKB1 loss leads to high expression of the cytokine leukemia-inhibitory factor (LIF), which through a cancer cell-autonomous autocrine loop, orchestrates the infiltration of immunosuppressive SiglecFHi neutrophils and Arg1+ interstitial macrophages. Genetic deletion of Lifr, the receptor for LIF, on Lkb1-mutant lung tumors revealed that autocrine LIF signaling induces tumor plasticity and the emergence of a Sox17+ dedifferentiated inflammatory cell state. Antibody-mediated LIF neutralization selectively eliminates the Sox17+ tumor cell state, reduces immunosuppressive myeloid cells, and enhances antitumor T-cell responses. Our study uncovers a novel LKB1-LIF axis driving immune evasion and identifies LIF as a potential therapeutic target in LKB1-mutant lung cancer. This work highlights the interplay between tumor genetics, cellular plasticity, and immune regulation in lung cancer progression. SIGNIFICANCE: LKB1-mutant lung cancers express LIF, which induces an immunosuppressive Sox17+ tumor state. Anti-LIF therapy eliminates this state and restores antitumor immunity, revealing a novel vulnerability in this aggressive cancer subtype lacking effective targeted therapies.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Pillai R, Rashidfarrokhi A, Hao Y, et al. LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer. Cancer Discov. 2026. PMID: 42008781. doi:10.1158/2159-8290.CD-25-0470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。